ISIS 2503 in Treating Patients With Metastatic and/or Locally Recurrent Colorectal Cancer

Stopped early · Phase 2

Conditions studied: Colorectal Cancer

In brief

RATIONALE: ISIS 2503 may kill cancer cells by inhibiting a gene that promotes the development and growth of cancer. PURPOSE: Phase II trial to study the effectiveness of ISIS 2503 in treating patients who have metastatic and/or locally recurrent colorectal cancer.

Key facts

Study ID

NCT00004193

Run by

University of Alabama at Birmingham

People needed

25

Starts

1999-01-01

Expected to finish

2000-11-01

Last updated by the study team

2013-04-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Alabama Comprehensive Cancer Center — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.